Company: BDRX
Filing Date: 2025-09-26
Form Type: F-3
Source: 0001214659-25-014255
Chunk: 106

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-09-26
Form: F-3
Chunk 106
---
 law or otherwise, or to make any demand upon us. Any holder of a unit may, without the consent of the related unit
agent or the holder of any other unit, enforce by appropriate legal action its rights as holder under any security included in the unit.

| 59 |

<div align='center'>EXPENSES</div>

The
following table sets forth the expenses, other than any underwriting discounts and commissions or agency fees and other items constituting
underwriters’ or agents’ compensation, expected to be incurred by us in connection with a possible offering of securities
registered under the registration statement of which this prospectus is a part. All amounts are estimated other than the SEC registration
fee.

| SEC registration fee         |     | $ | 12,818 | (1 | ) |
| FINRA filing fee             |     |   |        | (2 | ) |
| Legal fees and expenses      |     |   |        | (2 | ) |
| Accounting fees and expenses |     |   |        | (2 | ) |
| Printing expenses            |     |   |        | (2 | ) |
| Miscellaneous expenses       |     |   |        | (2 | ) |
| Total                        |     | $ |        | (2 | ) |

| (1) | In accordance with Rule 415(a)(6), includes certain fees previously                                                             
 paid in respect of unsold securities previously registered under the registrant’s registration statements on Form F-3 (File No. 
 333-267392), as further described in the Filing Fee Table included as Exhibit 107 hereto.                                       |

| (2) | These fees are calculated based on the securities offered and the number of issuances and accordingly cannot be estimated at this 
 time.                                                                                                                             |

| 60 |

<div align='center'>LEGAL MATTERS</div>

Unless the applicable prospectus
supplement indicates otherwise, the validity of the debt securities, warrants, rights and units governed by U.S. law and certain other
matters of U.S. law will be passed upon for us by Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. Unless the applicable prospectus
supplement indicates otherwise, the validity of our Ordinary Shares, including Ordinary Shares underlying the Depositary Shares, and certain
matters governed by English law will be passed on for us by Stephenson Harwood LLP. Additional legal matters may be passed upon for any
underwriters